Aimmune Therapeutics, Inc. - FORM S-1/A - EX-23.1 - July 27, 2015

Attached files

file filename
S-1/A - S-1/A - Aimmune Therapeutics, Inc.d932346ds1a.htm
EX-4.2 - EX-4.2 - Aimmune Therapeutics, Inc.d932346dex42.htm
EX-1.1 - EX-1.1 - Aimmune Therapeutics, Inc.d932346dex11.htm
EX-3.3 - EX-3.3 - Aimmune Therapeutics, Inc.d932346dex33.htm
EX-3.2 - EX-3.2 - Aimmune Therapeutics, Inc.d932346dex32.htm
EX-5.1 - EX-5.1 - Aimmune Therapeutics, Inc.d932346dex51.htm
EX-3.5 - EX-3.5 - Aimmune Therapeutics, Inc.d932346dex35.htm
EX-10.7 - EX-10.7 - Aimmune Therapeutics, Inc.d932346dex107.htm
EX-10.8 - EX-10.8 - Aimmune Therapeutics, Inc.d932346dex108.htm
EX-10.9 - EX-10.9 - Aimmune Therapeutics, Inc.d932346dex109.htm
EX-21.1 - EX-21.1 - Aimmune Therapeutics, Inc.d932346dex211.htm
EX-10.12 - EX-10.12 - Aimmune Therapeutics, Inc.d932346dex1012.htm
EX-10.10 - EX-10.10 - Aimmune Therapeutics, Inc.d932346dex1010.htm
EX-10.15 - EX-10.15 - Aimmune Therapeutics, Inc.d932346dex1015.htm
EX-10.11 - EX-10.11 - Aimmune Therapeutics, Inc.d932346dex1011.htm
EX-10.13 - EX-10.13 - Aimmune Therapeutics, Inc.d932346dex1013.htm
EX-10.6(C) - EX-10.6(C) - Aimmune Therapeutics, Inc.d932346dex106c.htm
EX-10.6(A) - EX-10.6(A) - Aimmune Therapeutics, Inc.d932346dex106a.htm
EX-10.6(B) - EX-10.6(B) - Aimmune Therapeutics, Inc.d932346dex106b.htm
EX-10.16 - EX-10.16 - Aimmune Therapeutics, Inc.d932346dex1016.htm

Exhibit 23.1

When the transaction referred to in Note 11 of the notes to the financial statements has been consummated, we will be in a position to render the following consent.

/s/ KPMG LLP

Consent of Independent Registered Public Accounting Firm

The Board of Directors

Aimmune Therapeutics,

Inc.:

We consent to the use of our report included herein and to the reference to our firm under the heading “Experts” in the prospectus.

San Francisco, California

                , 2015

Aimmune Therapeutics, Inc. Reports